Free Biopharma Daily Stock Updates - 09/28/21

$XBI $127.74 -3.16%

---

Covid Updates

$HGEN -3.6% Humanigen Announces the European Medicines Agency Has Appointed a Rapporteur and Co-rapporteur as Part of the Process Related to the Planned Submission of a Marketing Authorization Application (MAA) for Lenzilumab. source

$BNTX -10.0% Pfizer and BioNTech Submit Initial Data to U.S. FDA From Pivotal Trial of COVID-19 Vaccine in Children 5 to <12 Years of Age. source

Pipeline Updates

$WVE -12.3% Wave Life Sciences Announces New Data for Leading RNA Editing Capability Across Multiple Tissues and Provides Update on AATD Program During Analyst and Investor Research Webcast. source

$ARQT -2.3% Arcutis Expands Patent Portfolio with Roflumilast Pharmacokinetics Patent. source

$SRRK -2.4% Scholar Rock Announces Issuance of U.S. Patent Protecting SRK-181, an Inhibitor of TGFβ1 Activation. source

$CBIO -2.8% -FDA Grants Catalyst Biosciences Orphan Drug Designation for MarzAA for the Treatment of Factor VII Deficiency. source

$MRNS 4.5% Marinus Pharmaceuticals Announces Virtual R&D Event on October 5, 2021. source

$MBIO -3.7% Mustang Bio Announces MB-101 (IL13Rα2‐targeted CAR T cells) Scientific Presentations at Upcoming Virtual Conferences. source

$IMPL +6.9% Impel NeuroPharma Announces Trudhesa™ (Dihydroergotamine Mesylate) Nasal Spray is Now Available for Prescription for the Acute Treatment of Migraine. source

$OTLK -3.5% Outlook Therapeutics Reports New Positive 12-Month Safety Data from Pivotal Phase 3 NORSE TWO Trial. source

$IMAB -0.9% I-Mab Announces Acceptance of IND Application from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors. source

$CUE +1.5% Cue Biopharma Announces Publication in Nature Journal, Scientific Reports, of Immunotherapeutic Platforms Immuno-STAT and Neo-STAT. source

$AGTC -3.7% AGTC Clinical Trial Investigators to Present Data from Ongoing XLRP and Achromatopsia Phase 1/2 Trials at the Fourteenth International Symposium on Retinal Degeneration. source

$ZGNX -2.3% Zogenix Submits Supplemental New Drug Application for FINTEPLA® (Fenfluramine) for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome. source

$ITRM +0.5% Iterum Therapeutics Provides Update from FDA Type A Meeting Regarding Oral Sulopenem. source

$LPCN -0.9% Lipocine Announces FDA Affirmation Of Class 1 NDA Resubmission For TLANDO®. source

$DRNA -3.4% Dicerna Initiates Phase 1 Clinical Trial of DCR-AUD, a Novel Investigational GalXC™ RNAi Therapeutic Candidate for the Treatment of Alcohol Use Disorder. source

$GRAY -5.8% Graybug Vision Reports Analysis of Data from the Six-Month Extension Study of the ALTISSIMO Phase 2b Trial in Wet AMD. source

$ALT -2.5% Altimmune Announces Positive Results From 12-week Phase 1 Clinical Trial of ALT-801 (Pemvidutide) in Overweight and Obese Volunteers. source

$GMDA -3.4% Gamida Cell to Host Virtual Event Highlighting GDA-201 and NAM-Enabled, Genetically Modified NK Cell Therapy Pipeline. source

$VALN 0% Valneva and Pfizer Report Further Positive Phase 2 Results, Including Booster Response, for Lyme Disease Vaccine Candidate. source

Finance & Business Updates

$ONTX -4.2% Onconova Therapeutics, Inc. Announces Closing of $21 Million Public Offering of Common Stock. source

$ENDP +0.6% Endo Reaches Agreement in Principle to Settle Louisiana Governmental Opioid Cases and Claims. source

$DMAC -1.7% DiaMedica Therapeutics Announces Closing of $30 Million Private Placement. source

$ARWR -7.5% Arrowhead Earns $10 Million Phase 1 Milestone Payment. source

---

Posted by FS